BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: BioWorld 2025 Year in ReviewBreaking News: BioWorld MedTech 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Photo of Stichodactyla helianthus anemone underwater
Aging

Sea anemone venom acts as a senolytic tool against cancer

Jan. 13, 2026
By Mar de Miguel
No Comments
The sea anemone Stichodactyla helianthus, which carpets the Caribbean seafloor, may hold the key to eliminating the senescent cells that survive cancer therapy. A collaboration led by Spanish scientists across several international research centers has discovered a new type of toxin that selectively eliminates senescent cancer cells.
Read More
Cancer

New CDK2 degraders disclosed in Triana Biomedicines patent

Jan. 12, 2026
Triana Biomedicines Inc. has divulged protein/nucleic acid degraders acting as cyclin-dependent kinase 2 (CDK2) degraders reported to be useful for the treatment of cancer.
Read More
3D illustration of cancer in crosshairs
Cancer

ADAR1-i-124 switches on antitumor immunity

Jan. 12, 2026
No Comments
Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process essential for regulating how cells respond to double-stranded RNA. ADAR1 generates two isoforms, p150 and p110, with distinct roles in cancer biology. Researchers from the Wistar Institute of Anatomy & Biology reported the preclinical characterization of ADAR1-i-124, an ADAR1 inhibitor designed for the treatment of cancer.
Read More
Cancer

Anti-FGFR1 therapy shows efficacy in colorectal cancer models

Jan. 12, 2026
No Comments
FGFR1 is a receptor tyrosine kinase that drives multiple intracellular signaling pathways involved in tumor cell proliferation, survival and progression. Because these pathways are frequently hyperactivated in colorectal cancer (CRC), FGFR1 represents a biologically relevant therapeutic target, and its inhibition has the potential to simultaneously suppress several oncogenic mechanisms.
Read More
Cancer

New GTPase KRAS inhibitors disclosed in SK Biopharmaceuticals patent

Jan. 12, 2026
SK Biopharmaceuticals Co. Ltd. has divulged GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Hangzhou Polymed Biopharmaceuticals patents new EGFR degradation inducers

Jan. 9, 2026
Hangzhou Polymed Biopharmaceuticals Inc. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR del19/Thr790Met/Cys797Ser triple mutant and/or EGFR Leu858Arg/Thr790Met/Cys797Ser triple mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
Read More
Immuno-oncology

Whitehawk announces IND progress for HWK-007, HWK-016

Jan. 9, 2026
No Comments
Whitehawk Therapeutics Inc. has obtained IND clearance from the FDA for HWK-007, its PTK7-targeted antibody-drug conjugate (ADC).
Read More
Immuno-oncology

A2 Biotherapeutics’ A2B-543 gains IND clearance

Jan. 9, 2026
No Comments
A2 Biotherapeutics Inc. has gained IND clearance from the FDA for A2B-543 for the treatment of germline heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced or metastatic solid tumors.
Read More
Cancer

Hetero Labs describes new tyrosine kinase inhibitors

Jan. 8, 2026
Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; CDHF12; PTC), tyrosine-protein kinase receptor UFO (AXL) and vascular endothelial growth factor receptor 2 (VEGFR2; FLK1) inhibitors reported to be useful for the treatment of cancer.
Read More
Immuno-oncology

Remegen divulges new antibody-drug conjugates

Jan. 8, 2026
Remegen Ltd. has synthesized antibody-drug conjugates consisting of anti-CDCP1 antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 3650 3651 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing